Welcome to our dedicated page for LIGAND PHARMACEUTICALS SEC filings (Ticker: LGND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LIGAND PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LIGAND PHARMACEUTICALS's regulatory disclosures and financial reporting.
LGND reported an insider sale. Stephen L. Sabba reported the sale of 2,034 common shares on 03/03/2026 with an aggregate figure shown as $409,851.00 in the filing. The notice also records an earlier exercised block of 1,000 shares on 03/05/2024 noted as "Exercised Shares" for cash.
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza exercised employee stock options and sold shares in the company on March 11, 2026. He exercised options covering 2,405 shares of common stock at an exercise price of $92.65 per share.
On the same day, he sold 3,057 shares of common stock at a price of $225.00 per share, leaving him with 21,010 shares held directly after the transactions. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025, and the stock option was fully vested and exercisable.
LGND filing: Notice of proposed sale under Rule 144 reporting planned dispositions of Common Stock by an insider. The excerpt lists 10b5-1 sales on 03/04/2026 for 13,423 shares and a sale on 12/12/2025 for 1,804 shares. It also shows exercises of stock options on 03/11/2026 (reported 2,405 shares) and earlier on 12/16/2025 (652 shares). The transactions are reported as planned 10b5-1 sales and option exercises; cash consideration amounts are shown for each sale row.
Ligand Pharmaceuticals’ Chief Legal Officer and Secretary Andrew Reardon reported a set of planned insider transactions in company stock. On March 4, 2026, he exercised employee stock options for 5,000 shares of common stock and then sold 5,000 common shares in a series of open-market trades.
The sales were executed at weighted-average prices disclosed in ranges between approximately $197.58 and $208.97, under a Rule 10b5-1 trading plan adopted on November 24, 2025. After these transactions, Reardon directly holds 36,869 common shares and 54,444 options, with the underlying option grant vesting over time.
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza reported option exercises and share sales in company stock. On March 4, 2026, he exercised employee stock options covering 2,073 shares of common stock and then sold 13,423 shares in open-market transactions.
The sales were executed at weighted-average prices generally between $198.37 and $208.95 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 21,662 shares of Ligand common stock.
Ligand Pharmaceuticals director Stephen L. Sabba exercised a stock option for 2,034 common shares at $69.51 per share and on the same day sold 2,034 shares at $201.50 per share in an open-market transaction. He now directly holds 33,793 common shares.
Ligand Pharmaceuticals director John W. Kozarich reported open-market sales of company common stock. On March 2, 2026, he sold a total of 467 shares in six separate transactions under a written trading plan adopted on March 7, 2025 in accordance with Rule 10b5-1.
The reported weighted-average prices for these sales ranged from about $197 to $203 per share, based on detailed price ranges in the filing. After completing the transactions, Kozarich directly owned 42,720 shares of Ligand Pharmaceuticals common stock.
LGND reported a proposed sale of common stock on a Form 144 with transactions dated 03/04/2026. The filing lists an $2,741,513.52 figure and the number 19,941,141 in the header. The excerpt shows planned sales tied to an exercise of stock options of 2,073 shares on 03/04/2026 and Restricted & Performance Stock Units of 11,350 shares with an award date of 12/31/2025. The sales are shown as common stock to be sold through Morgan Stanley Smith Barney LLC.